1. Inicio
  2. Publicaciones
  3. PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review

PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Sobas, M
  • Talarn-Forcadell, MC
  • Escoda, L
  • Garcia-Perez, MJ
  • Mariz, J
  • Mela-Osorio, MJ
  • Fernandez, I
  • Alonso-Dominguez, JM
  • Cornago-Navascues, J
  • Rodriguez-Macias, G
  • Amutio, ME
  • Rodriguez-Medina, C
  • Esteve, J
  • Sokol, A
  • Murciano-Carrillo, T
  • Calasanz, MJ
  • Barrios, M

Grupos

Abstract

It has been suggested that 1-2% of acute promyelocytic leukemia (APL) patients present variant rearrangements of retinoic acid receptor alpha (RAR alpha) fusion gene, with the promyelocytic leukaemia zinc finger (PLZF)/RAR(alpha) being the most frequent. Resistance to all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested in PLZF/RAR(alpha) and other variant APLs. Herein, we analyze the incidence, characteristics, and outcomes of variant APLs reported to the multinational PETHEMA (Programa para el Tratamiento de Hemopatias Malignas) registry, and we perform a systematic review in order to shed light on strategies to improve management of these extremely rare diseases. Of 2895 patients with genetically confirmed APL in the PETHEMA registry, 11 had variant APL (0.4%) (9 PLZF-RAR(alpha) and 2 NPM1-RAR(alpha)), 9 were men, with median age of 44.6 years (3 months to 76 years), median leucocytes (WBC) 16.8 x 10(9)/L, and frequent coagulopathy. Eight patients were treated with ATRA plus chemotherapy-based regimens, and 3 with chemotherapy-based. As compared to previous reports, complete remission and survival was slightly better in our cohort, with 73% complete remission (CR) and 73% survival despite a high relapse rate (43%). After analyzing our series and performing a comprehensive and critical review of the literature, strong recommendations on appropriate management of variant APL are not possible due to the low number and heterogeneity of patients reported so far.

Datos de la publicación

ISSN/ISSNe:
2072-6694, 2072-6694

Cancers  MDPI

Tipo:
Review
Páginas:
-
PubMed:
32455804
Factor de Impacto:
1,818 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 26

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • variant; acute promyelocytic leukemia; systematic review; characteristics; outcomes

Campos de Estudio

Cita

Compartir